Multiple sclerosis, N. Engl. J. Med, vol.378, pp.169-180, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01480156
Science is 1% inspiration and 99% biomarkers, Mult. Scler. Houndmills Basingstoke Engl, vol.58517, pp.70936-70938, 2017. ,
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis, Ann. Neurol, vol.81, pp.857-870, 2017. ,
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response, Neurology, vol.92, pp.1007-1015, 2019. ,
Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis, Mult. Scler. J, vol.58518, pp.76566-76572, 2018. ,
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis, Brain J. Neurol, 2018. ,
Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years, JAMA Neurol, 2019. ,
Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study, Ann. Clin. Transl. Neurol, vol.6, pp.1757-1770, 2019. ,
Serum GFAP as a biomarker for disease severity in multiple sclerosis, Sci. Rep, vol.8, p.14798, 2018. ,
, Scientific RepoRtS |, vol.10, p.10923, 2020.
Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity, Mult. Scler. Houndmills Basingstoke Engl, 2018. ,
Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker, Front. Neurol, vol.10, p.280, 2019. ,
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, vol.17, pp.162-173, 2018. ,
Automated detection of white matter and cortical lesions in early stages of multiple sclerosis, J. Magn. Reson. Imaging JMRI, vol.43, pp.1445-1454, 2016. ,
Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI, NeuroImage, vol.32, pp.1205-1215, 2006. ,
Partial volume-aware assessment of multiple sclerosis lesions, NeuroImage Clin, vol.18, pp.245-253, 2018. ,
Neurofilament and glial fibrillary acidic protein in multiple sclerosis, Neurology, vol.63, pp.1586-1590, 2004. ,
Assessing tissue damage in multiple sclerosis: a biomarker approach, Acta Neurol. Scand, vol.130, pp.81-89, 2014. ,
Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD, Neurology, vol.93, pp.1299-1311, 2019. ,
Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis, J. Neuroimmunol, vol.299, pp.112-117, 2016. ,
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis, Mult. Scler. J, vol.21, pp.550-561, 2015. ,
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS, Neurol. Neuroimmunol. Neuroinflammation, vol.3, p.271, 2016. ,